Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892025 | 1.00 | CYP1A2 (0.41) | CYP1A2TSHRNAAASIGMAR1EPHX1 | |
| SCHEMBL22042665 | 1.00 | CYP1A2 (0.41) | CYP1A2TSHRNAAASIGMAR1EPHX1 | |
| SCHEMBL8770230 | 1.00 | CYP1A2 (0.41) | CYP1A2TSHRNAAASIGMAR1EPHX1 | |
| SCHEMBL6715525 | 1.00 | CYP1A2 (0.41) | CYP1A2TSHRNAAASIGMAR1EPHX1 | |
| SCHEMBL22042671 | 1.00 | CYP1A2 (0.41) | CYP1A2TSHRNAAASIGMAR1EPHX1 | |
| SCHEMBL22042602 | 1.00 | CYP1A2 (0.41) | CYP1A2TSHRNAAASIGMAR1EPHX1 | |
| SCHEMBL6263591 | 1.00 | CYP1A2 (0.41) | CYP1A2TSHRNAAASIGMAR1EPHX1 | |
| SCHEMBL6716866 | 1.00 | CYP1A2 (0.41) | CYP1A2TSHRNAAASIGMAR1EPHX1 | |
| SCHEMBL8769510 | 1.00 | CYP1A2 (0.41) | CYP1A2TSHRNAAASIGMAR1EPHX1 | |
| SCHEMBL65833 | 1.00 | CYP1A2 (0.41) | CYP1A2TSHRNAAASIGMAR1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199625-A1 | BICYCLIC HETEROCYCLIC FGFR4 INHIBITOR, PHARMACEUTICAL COMPOSITION AND PREPARATION COMPRISING SAME, AND APPLICATION THEREOF | HANGZHOU APELOA MEDICINE RESEARCH INSTITUTE CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| EP-4317143-A1 | BICYCLIC HETEROCYCLIC FGFR4 INHIBITOR, PHARMACEUTICAL COMPOSITION AND PREPARATION COMPRISING SAME, AND APPLICATION THEREOF | Hangzhou Apeloa Medicine Research Institute Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| CN-117062809-A | Bicyclic heterocyclic FGFR4 inhibitors, pharmaceutical compositions and formulations comprising the same and uses thereof | 杭州普洛药物研究院有限公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2021219495-A1 | METHODS FOR TREATING OR PREVENTING A VIRAL INFECTION OR INHIBITING VIRAL REPLICATION | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-11-04 | — | — | WO | disclosed |
| US-20210338626-A1 | METHODS FOR TREATING OR PREVENTING A VIRAL INFECTION OR INHIBITING VIRAL REPLICATION | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-11-04 | — | — | US | disclosed |
| WO-2020149553-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR TREATMENT OF KINASE-RELATED DISEASE | 주식회사 보로노이 | 2020-07-23 | — | — | WO | disclosed |
| CN-109021982-A | Liquid crystal alignment agent, manufacturing method of liquid crystal alignment film and liquid crystal display assembly | 奇美实业股份有限公司 | 2018-12-18 | — | — | CN | disclosed |
| US-9261783-B2 | Fluorinated ester monomer, making method, fluorinated ester polymer, and difluorohydroxycarboxylic acid | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-9000045-B2 | CETP activity inhibitors | JAPAN TOBACCO INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| WO-2004082593-A2 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | JAPAN TOBACCO INC. (JP) | 2004-09-30 | — | — | WO | disclosed |
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| US-6753346-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS | JAPAN TOBACCO INC. (JP) | 2004-06-22 | — | — | US | disclosed |
| EP-1323726-A1 | ERYTHROMYCIN DERIVATIVES AND MEDICINES CONTAINING THE SAME | HOKURIKU SEIYAKU CO., LTD. (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | JAPAN TOBACCO, INC., A JAPAN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| US-6426365-B1 | Anticholesterol agents; Cholesterol ester transfer protein (CETP); including dalcetrapib, S-(2-(((1-(2-ethylbutyl)cyclohexyl)carbonyl)amino) phenyl) 2-methylpropanethioate | JAPAN TOBACCO INC. (JP) | 2002-07-30 | — | — | US | disclosed |
| EP-1167375-A1 | ERYTHROMYCIN DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-1044985-A1 | ERYTHROMYCIN DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2000-10-18 | — | — | EP | disclosed |
| EP-1020439-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2000-07-19 | — | — | EP | disclosed |
| CN-1252053-A | Cetp activity inhibitors | JAPAN TOBACCO INC (JP) | 2000-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | MAPRE1, MAPRE2, MRPS27 | CYP1A2 2639/4885TSHR 925/4885NAAA 1333/4885 |
| US-20210338626-A1 | METHODS FOR TREATING OR PREVENTING A VIRAL INFECTION OR INHIBITING VIRAL REPLICATION | ACE, ACE2, REN | CYP1A2 3967/4885TSHR 4080/4885NAAA 276/4885 |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | CETP, CES1, PON1 | CYP1A2 1243/4885TSHR 3032/4885NAAA 688/4885 |
| US-20240199625-A1 | BICYCLIC HETEROCYCLIC FGFR4 INHIBITOR, PHARMACEUTICAL COMPOSITION AND PREPARATION COMPRISING SAME, AND APPLICATION THEREOF | FGFR4, FGFR3, FGFR1 | CYP1A2 505/4885TSHR 3669/4885NAAA 4254/4885 |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | CYP1A2 1703/4885TSHR 1974/4885NAAA 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.